INVA Live signals | Maximize Profits with Getagraph.com

SELL 103878 min ago

@ $15.84

Issued: 14 Feb 2024 @ 15:17

Return: -3.66%

Previous signal: Feb 14 - 13:26

Previous signal: Buy

Return: 0.54 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	279 142
Average Volume	706 679
Market Cap	964.85M
EPS	$0 ( 2024-02-27 )
Next earnings date	( $0.170 ) 2024-05-07
Last Dividend	$0.250 ( 2015-09-08 )
Next Dividend	$0 ( N/A )
P/E	6.94
ATR14	$0.0120 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Basso Stephen	Buy	25 899	Non-statutory Stock Option
2024-03-05	Basso Stephen	Buy	12 096	Common Stock
2024-03-05	Ronsheim Matthew	Buy	27 338	Non-statutory Stock Option
2024-03-05	Ronsheim Matthew	Buy	12 768	Common Stock
2024-03-05	Zhen Marianne	Buy	23 022	Non-statutory Stock Option

INSIDER POWER
89.75
Last 96 transactions
Buy: 2 118 652 \| Sell: 32 343 813

Volume Correlation

Long: 0.60 (weak)

Short: 0.84 (strong)

Signal:(62.689) Same movement expected

Innoviva Inc Correlation

10 Most Positive Correlations
ESSA	0.92
ONEM	0.92
NAKD	0.911
AADI	0.909
AROW	0.908
DSWL	0.906
CMLS	0.906
AZTA	0.905
BSRR	0.904
UK	0.902

10 Most Negative Correlations
NEO	-0.927
TMDX	-0.919
XLRN	-0.916
MORF	-0.916
HAPP	-0.915
SVC	-0.914
ACVA	-0.913
SGTX	-0.911
MHUA	-0.909
SJ	-0.909

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Innoviva Inc Correlation - Currency/Commodity

-0.20
( neutral )

-0.12
( neutral )

0.00
( neutral )

-0.57
( weak negative )

0.00
( neutral )

-0.18
( neutral )

Innoviva Inc Financials

Annual	2023
Revenue:	$324.26M
Gross Profit:	$245.92M (75.84 %)
EPS:	$-1.910

FY	2023
Revenue:	$324.26M
Gross Profit:	$245.92M (75.84 %)
EPS:	$-1.910

FY	2022
Revenue:	$331.34M
Gross Profit:	$317.55M (95.84 %)
EPS:	$-1.080

FY	2021
Revenue:	$391.87M
Gross Profit:	$0.00 (0.00 %)
EPS:	$2.62

Financial Reports:

No articles found.

Innoviva Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Innoviva Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.68 - No dividend growth expected in the near future

Information

First Dividend	$0.250	2014-08-26
Last Dividend	$0.250	2015-09-08
Next Dividend	$0	N/A
Payout Date	2015-09-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	3.77	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.68
Div. Directional Score	7.39	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

3.77

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2014	$0.500	1.84%
2015	$0.750	5.65%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.573	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.145	1.200	5.18	6.22	[0 - 0.3]
returnOnEquityTTM	0.297	1.500	7.81	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.03	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	5.07	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.360	-1.500	4.00	-6.00	[0 - 0.6]
interestCoverageTTM	9.70	1.000	7.52	7.52	[3 - 30]
operatingCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.21	2.00	8.90	10.00	[0 - 20]
debtEquityRatioTTM	0.663	-1.500	7.35	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.832	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.592	1.000	0.162	0.162	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.315	1.000	9.36	9.36	[0.2 - 2]
assetTurnoverTTM	0.252	0.800	-1.650	-1.320	[0.5 - 2]
Total Score				11.10

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.31	1.000	9.56	0	[1 - 100]
returnOnEquityTTM	0.297	2.50	8.59	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.100	1.500	-2.66	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.449	1.000	1.265	0	[0.1 - 0.5]
Total Score				3.68

Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.